Financial Comparison: Spruce Biosciences (SPRBD) & Its Peers

Insider & Institutional Ownership

91.7% of Spruce Biosciences shares are owned by institutional investors. Comparatively, 24.8% of shares of all “Biotechnology” companies are owned by institutional investors. 6.9% of Spruce Biosciences shares are owned by company insiders. Comparatively, 20.8% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Spruce Biosciences and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Spruce Biosciences	N/A	N/A	N/A
Spruce Biosciences Competitors	-15,247.28%	32.46%	-33.43%

Volatility and Risk

Spruce Biosciences has a beta of 2.43, suggesting that its stock price is 143% more volatile than the S&P 500. Comparatively, Spruce Biosciences’ competitors have a beta of 0.97, suggesting that their average stock price is 3% less volatile than the S&P 500.

Earnings & Valuation

This table compares Spruce Biosciences and its competitors top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Spruce Biosciences	N/A	N/A	-0.11
Spruce Biosciences Competitors	$163.42 million	-$11.65 million	-436.19

Spruce Biosciences’ competitors have higher revenue, but lower earnings than Spruce Biosciences. Spruce Biosciences is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Summary

Spruce Biosciences beats its competitors on 5 of the 8 factors compared.